XML 16 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 7,403,176 $ 5,794,272
Short-term investment securities 772,804 6,847,270
Interest receivable 9,822 58,285
Accounts receivable 417,878 330,001
Prepaid expenses and other current assets 484,188 392,236
Total current assets 9,087,868 13,422,064
Non-current assets:    
Operating lease right-of-use asset, net 153,112 0
Investment in Alphazyme 0 284,709
Other assets 14,586 6,045
Total assets 9,255,566 13,712,818
Current liabilities:    
Accounts payable 600,148 1,276,313
Accrued expenses 620,242 955,081
Deferred research and development obligations 13,897 40,743
Deferred license revenue, current portion 176,471 176,471
Operating lease liability, current portion 46,599 0
Total current liabilities 1,457,357 2,448,608
Deferred license revenue, net of current portion 44,118 176,471
Operating lease liability, net of current portion 101,567 0
Total liabilities 1,603,042 2,625,079
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Authorized shares - 100,000,000; issued shares - 41,064,563 and 40,816,602, outstanding shares - 28,811,061 and 28,563,100 as of September 30, 2023 and December 31, 2022, respectively 41,065 40,817
Additional paid-in capital 104,746,897 103,458,697
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (78,205,523) (73,481,860)
Total stockholders’ equity 7,652,524 11,087,739
Total liabilities and stockholders’ equity $ 9,255,566 $ 13,712,818